Terumo and UMCU Strengthen their Partnership to Develop Solutions in Interventional Oncology

Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successfully collaborated in technology transfer, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Transarterial radioembolization, TARE) for the treatment of unresectable liver tumors.

The MoU marks the continuation of the existing partnership and confirms the shared interest of both parties to enhance education and innovations to develop meaningful solutions that provide significant clinical benefits to patients with cancer and increase their access to treatments.

Quirem Medical, a wholly owned subsidiary of Terumo since July 2020,  based in Deventer, originated as a spin-off from the UMC Utrecht in 2013. Quirem Medical manufactures QuiremSpheres™, the only commercially available microspheres containing the radioactive isotope Holmium-166. Trials have shown the safety and efficacy of holmium microspheres in the treatment of unresectable liver tumors. Quirem Medical also manufactures the SIRT work-up product QuiremScout™ Holmium-166 Microspheres, which is used prior to the therapy to select patients and plan the SIRT procedure. Across Europe, hundreds of patients are treated with QuiremSpheres™ Holmium-166 Microspheres and QuiremScout™ Holmium-166 Microspheres every year.

With the acquisition of Quirem Medical in 2020 and the creation of the Global TIO team in 2021, we see great opportunities to leverage the broad Terumo technology base in interventional oncology for improved cancer care. The UMC Utrecht has proven a highly reliable, professional & innovative clinical partner with a strong focus on image guided therapies in cancer care. As such, the UMC Utrecht is a partner of choice in this journey; and we look forward to a successful continuation of our close collaboration in education, innovation and data generation to contribute to society through healthcare together.” Says Ghada Farah, Senior Vice President Terumo Interventional Systems EMEA.

Terumo, a global leader in medical technology, announced on April 12, 2021 the launch of its Global Therapeutic Interventional Oncology (TIO) team. This reflects Terumo’s aspiration to be a global leader in the field of Interventional Oncology by focusing on improving patient’s quality of life and survival.

“Terumo and the UMC Utrecht have a fruitful history of collaboration on QuiremSpheres™ Holmium-166 Microspheres for radioembolization of liver tumors. This Memorandum of Understanding underlines the collaboration that is already there for QuiremSpheres™ Holmium-166 Microspheres and the ambition to collaborate in the broader range of interventional oncology, including tumor ablation and chemoembolization. Terumo’s dedication to improve patient care and the company’s global reach make Terumo an ideal partner for this journey.” says Dr. Maarten Smits, Interventional Radiologist, UMC Utrecht

SourceTerumo
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy